新城疫病毒抗恶性肿瘤研究进展
|
摘要
溶瘤病毒疗法是临床治疗恶性肿瘤的新突破,其通过感染肿瘤细胞,引起病毒性细胞病变反应并诱发宿主抗肿瘤免疫,从而选择性杀死肿瘤细胞。新城疫病毒(NDV)是一种禽副黏病毒,对小鼠和人的抗肿瘤和免疫刺激作用已在临床前及临床研究中被证实,是最具潜力的溶瘤病毒之一。随着反向遗传学技术的不断成熟,使用该技术构建的以NDV为载体的插入外源基因重组NDV在免疫活性肿瘤模型中的研究成为热点。重组NDV不但可以稳定表达外源治疗基因,还可以增强病毒杀伤肿瘤和诱导宿主抗肿瘤免疫应答的能力。但其治疗恶性肿瘤的效果未来需大量临床试验验证。
Oncolytic virus therapy is a new breakthrough in the clinical treatment of malignant tumors,which selectively kills tumor cells by infecting tumor cells,causing viral cytopathic effects and inducing host anti-tumor immune responses.Newcastle disease virus( NDV) is an avian paramyxovirus,the anti-tumor and immunostimulatory effects of which on mouse and human have been confirmed in preclinical and clinical studies,and it is one of the most promising oncolytic viruses.With the development of reverse genetics technology,the study of recombinant NDV with NDV as a vector for the insertion of foreign genes in the immunologically active tumor model has become a hot topic. Recombinant NDV can not only stably express exogenous therapeutic genes,but also enhance the ability of the virus to kill tumors and induce host anti-tumor immune responses. However,the efficacy in the treatment of malignant tumors needs to be verified by a large number of clinical trials in the future.
Oncolytic virus therapy is a new breakthrough in the clinical treatment of malignant tumors,which selectively kills tumor cells by infecting tumor cells,causing viral cytopathic effects and inducing host anti-tumor immune responses.Newcastle disease virus( NDV) is an avian paramyxovirus,the anti-tumor and immunostimulatory effects of which on mouse and human have been confirmed in preclinical and clinical studies,and it is one of the most promising oncolytic viruses.With the development of reverse genetics technology,the study of recombinant NDV with NDV as a vector for the insertion of foreign genes in the immunologically active tumor model has become a hot topic. Recombinant NDV can not only stably express exogenous therapeutic genes,but also enhance the ability of the virus to kill tumors and induce host anti-tumor immune responses. However,the efficacy in the treatment of malignant tumors needs to be verified by a large number of clinical trials in the future.
引文
[1]Chen B,Dai W,He B,et al.Current multistage drug delivery systems based on the tumor microenvironment[J].Theranostics,2017,7(3):538-558.
[2]Torre LA,Bray F,Siegel RL,et al.Global cancer statistics,2012[J].CA Cancer J Clin,2015,65(2):87-108.
[3]Kaufman HL,Kohlhapp FJ,Zloza A.Oncolytic viruses:A new class of immunotherapy drugs[J].Nat Rev Drug Discov,2015,14(9):642-662.
[4]Schirrmacher V.Fifty years of clinical application of Newcastle disease virus:Time to celebrate![J].Biomedicines,2016,4(3).pii:E16.
[5]Peeters BP,Gruijthuijsen YK,de Leeuw OS,et al.Genome replication of Newcastle disease virus:Involvement of the rule-of-six[J].Arch Virol,2000,145(9):1829-1845.
[6]Chumbe A,Izquierdo-Lara R,Calderón K,et al.Development of a novel Newcastle disease virus(NDV)neutralization test based on recombinant NDV expressing enhanced green fluorescent protein[J].Virol J,2017,14(1):232.
[7]Fiola C,Peeters B,Fournier P,et al.Tumor selective replication of Newcastle disease virus:Association with defects of tumor cells in antiviral defence[J].Int J Cancer,2006,119(2):328-338.
[8]Schirrmacher V.Oncolytic Newcastle disease virus as a prospective anti-cancer therapy.A biologic agent with potential to break therapy resistance[J].Expert Opin Biol Ther,2015,15(12):1757-1771.
[9]Schirrmacher V.Immunobiology of Newcastle disease virus and its use for prophylactic vaccination in poultry and as adjuvant for therapeutic vaccination in cancer patients[J].Int J Mol Sci,2017,18(5).pii:E1103.
[10]Elankumaran S,Rockemann D,Samal SK.Newcastle disease virus exerts oncolysis by both intrinsic and extrinsic caspase-dependent pathways of cell death[J].J Virol,2006,80(15):7522-7534.
[11]Kalyanasundram J,Hamid A,Yusoff K,et al.Newcastle disease virus strain AF2240 as an oncolytic virus:A review[J].Acta Trop,2018,183:126-133.
[12]Ghrici M,El Zowalaty M,Omar AR,et al.Induction of apoptosis in MCF-7 cells by the hemagglutinin-neuraminidase glycoprotein of Newcastle disease virus Malaysian strain AF2240[J].Oncol Rep,2013,30(3):1035-1044.
[13]Molouki A,Hsu YT,Jahanshiri F,et al.Newcastle disease virus infection promotes Bax redistribution to mitochondria and cell death in He La cells[J].Intervirology,2010,53(2):87-94.
[14]Molouki A,Yusoff K.NDV-induced apoptosis in absence of Bax;evidence of involvement of apoptotic proteins upstream of mitochondria[J].Virol J,2012,9:179.
[15]Rubinsztein DC,Codogno P,Levine B.Autophagy modulation as a potential therapeutic target for diverse diseases[J].Nat Rev Drug Discov,2012,11(9):709-730.
[16]Meng C,Zhou Z,Jiang K,et al.Newcastle disease virus triggers autophagy in U251 glioma cells to enhance virus replication[J].Arch Virol,2012,157(6):1011-1018.
[17]Sun Y,Yu S,Ding N,et al.Autophagy benefits the replication of Newcastle disease virus in chicken cells and tissues[J].J Virol,2014,88(1):525-537.
[18]Meng G,Xia M,Wang D,et al.Mitophagy promotes replication of oncolytic Newcastle disease virus by blocking intrinsic apoptosis in lung cancer cells[J].Oncotarget,2014,5(15):6365-6374.
[19]Galluzzi L,BuquéA,Kepp O,et al.Immunogenic cell death in cancer and infectious disease[J].Nat Rev Immunol,2017,17(2):97-111.
[20]van Vloten JP,Workenhe ST,Wootton SK,et al.Critical interactions between immunogenic cancer cell death,oncolytic viruses,and the immune system define the rational design of combination immunotherapies[J].J Immunol,2018,200(2):450-458.
[21]Ye T,Jiang K,Wei L,et al.Oncolytic Newcastle disease virus induces autophagy-dependent immunogenic cell death in lung cancer cells[J].Am J Cancer Res,2018,8(8):1514-1527.
[22]Koks CA,Garg AD,Ehrhardt M,et al.Newcastle disease virotherapy induces long-term survival and tumor-specific immune memory in orthotopic glioma through the induction of immunogenic cell death[J].Int J Cancer,2015,136(5):E313-325.
[23]Zamarin D,Holmgaard RB,Subudhi SK,et al.Localized oncolytic virotherapy overcomes systemic tumor resistance to immune checkpoint blockade immunotherapy[J].Sci Transl Med,2014,6(226):226ra32.
[24]Wei D,Li Q,Wang XL,et al.Oncolytic Newcastle disease virus expressing chimeric antibody enhanced anti-tumor efficacy in orthotopic hepatoma-bearing mice[J].J Exp Clin Cancer Res,2015,34:153.
[25]Bu X,Li M,Zhao Y,et al.Genetically engineered Newcastle disease virus expressing human interferon-λ1 induces apoptosis in gastric adenocarcinoma cells and modulates the Th1/Th2 immune response[J].Oncol Rep,2016,36(3):1393-1402.
[26]Jiang K,Song C,Kong L,et al.Recombinant oncolytic Newcastle disease virus displays antitumor activities in anaplastic thyroid cancer cells[J].BMC Cancer,2018,18(1):746.
[27]Raghunath S,Pudupakam RS,Allen A,et al.Genetically engineered oncolytic Newcastle disease virus mediates cytolysis of prostate cancer stem like cells[J].J Biotechnol,2017,260:91-97.
[28]Farkona S,Diamandis EP,Blasutig IM.Cancer immunotherapy:the beginning of the end of cancer?[J].BMC Med,2016,14:73.
[29]van der Burg SH,Arens R,Ossendorp F,et al.Vaccines for established cancer:Overcoming the challenges posed by immune evasion[J].Nat Rev Cancer,2016,16(4):219-233.
[30]García-Martínez E,Smith M,BuquéA,et al.Trial Watch:Immunostimulation with recombinant cytokines for cancer therapy[J].Oncoimmunology,2018,7(6):e1433982.
[31]Papaioannou NE,Beniata OV,Vitsos P,et al.Harnessing the immune system to improve cancer therapy[J].Ann Transl Med,2016,4(14):261.
[32]Janke M,Peeters B,de Leeuw O,et al.Recombinant Newcastle disease virus(NDV)with inserted gene coding for GM-CSF as a new vector for cancer immunogene therapy[J].Gene Ther,2007,14(23):1639-1649.
[33]Bai F,Niu Z,Tian H,et al.Genetically engineered Newcastle disease virus expressing interleukin 2 is a potential drug candidate for cancer immunotherapy[J].Immunol Lett,2014,159(1/2):36-46.
[34]Ren G,Tian G,Liu Y,et al.Recombinant Newcastle disease virus encoding IL-12 and/or IL-2 as potential candidate for hepatoma carcinoma therapy[J].Technol Cancer Res Treat,2016,15(5):NP83-94.
[35]Wolchok JD,Chiarion-Sileni V,Gonzalez R,et al.Overall survival with combined nivolumab and ipilimumab in advanced melanoma[J].N Engl J Med,2017,377(14):1345-1356.
[36]Zamarin D,Holmgaard RB,Ricca J,et al.Intratumoral modulation of the inducible co-stimulator ICOS by recombinant oncolytic virus promotes systemic anti-tumour immunity[J].Nat Commun,2017,8:14340.
[37]Soussi T,Dehouche K,Beroud C.p53 website and analysis of p53gene mutations in human cancer:Forging a link between epidemiology and carcinogenesis[J].Hum Mutat,2000,15(1):105-113.
[38]Diller L,Kassel J,Nelson CE,et al.p53 functions as a cell cycle control protein in osteosarcomas[J].Mol Cell Biol,1990,10(11):5772-5781.
[39]An Y,Liu T,He J,et al.Recombinant Newcastle disease virus expressing P53 demonstrates promising antitumor efficiency in hepatoma model[J].J Biomed Sci,2016,23(1):55.
[40]Fan X,Lu H,Cui Y,et al.Overexpression of p53 delivered using recombinant NDV induces apoptosis in glioma cells by regulating the apoptotic signaling pathway[J].Exp Ther Med,2018,15(5):4522-4530.
[41]Cuadrado-Castano S,Ayllon J,Mansour M,et al.Enhancement of the proapoptotic properties of newcastle disease virus promotes tumor remission in syngeneic murine cancer models[J].Mol Cancer Ther,2015,14(5):1247-1258.
[42]Wu Y,He J,Geng J,et al.Recombinant Newcastle disease virus expressing human TRAIL as a potential candidate for hepatoma therapy[J].Eur J Pharmacol,2017,802:85-92.
[2]Torre LA,Bray F,Siegel RL,et al.Global cancer statistics,2012[J].CA Cancer J Clin,2015,65(2):87-108.
[3]Kaufman HL,Kohlhapp FJ,Zloza A.Oncolytic viruses:A new class of immunotherapy drugs[J].Nat Rev Drug Discov,2015,14(9):642-662.
[4]Schirrmacher V.Fifty years of clinical application of Newcastle disease virus:Time to celebrate![J].Biomedicines,2016,4(3).pii:E16.
[5]Peeters BP,Gruijthuijsen YK,de Leeuw OS,et al.Genome replication of Newcastle disease virus:Involvement of the rule-of-six[J].Arch Virol,2000,145(9):1829-1845.
[6]Chumbe A,Izquierdo-Lara R,Calderón K,et al.Development of a novel Newcastle disease virus(NDV)neutralization test based on recombinant NDV expressing enhanced green fluorescent protein[J].Virol J,2017,14(1):232.
[7]Fiola C,Peeters B,Fournier P,et al.Tumor selective replication of Newcastle disease virus:Association with defects of tumor cells in antiviral defence[J].Int J Cancer,2006,119(2):328-338.
[8]Schirrmacher V.Oncolytic Newcastle disease virus as a prospective anti-cancer therapy.A biologic agent with potential to break therapy resistance[J].Expert Opin Biol Ther,2015,15(12):1757-1771.
[9]Schirrmacher V.Immunobiology of Newcastle disease virus and its use for prophylactic vaccination in poultry and as adjuvant for therapeutic vaccination in cancer patients[J].Int J Mol Sci,2017,18(5).pii:E1103.
[10]Elankumaran S,Rockemann D,Samal SK.Newcastle disease virus exerts oncolysis by both intrinsic and extrinsic caspase-dependent pathways of cell death[J].J Virol,2006,80(15):7522-7534.
[11]Kalyanasundram J,Hamid A,Yusoff K,et al.Newcastle disease virus strain AF2240 as an oncolytic virus:A review[J].Acta Trop,2018,183:126-133.
[12]Ghrici M,El Zowalaty M,Omar AR,et al.Induction of apoptosis in MCF-7 cells by the hemagglutinin-neuraminidase glycoprotein of Newcastle disease virus Malaysian strain AF2240[J].Oncol Rep,2013,30(3):1035-1044.
[13]Molouki A,Hsu YT,Jahanshiri F,et al.Newcastle disease virus infection promotes Bax redistribution to mitochondria and cell death in He La cells[J].Intervirology,2010,53(2):87-94.
[14]Molouki A,Yusoff K.NDV-induced apoptosis in absence of Bax;evidence of involvement of apoptotic proteins upstream of mitochondria[J].Virol J,2012,9:179.
[15]Rubinsztein DC,Codogno P,Levine B.Autophagy modulation as a potential therapeutic target for diverse diseases[J].Nat Rev Drug Discov,2012,11(9):709-730.
[16]Meng C,Zhou Z,Jiang K,et al.Newcastle disease virus triggers autophagy in U251 glioma cells to enhance virus replication[J].Arch Virol,2012,157(6):1011-1018.
[17]Sun Y,Yu S,Ding N,et al.Autophagy benefits the replication of Newcastle disease virus in chicken cells and tissues[J].J Virol,2014,88(1):525-537.
[18]Meng G,Xia M,Wang D,et al.Mitophagy promotes replication of oncolytic Newcastle disease virus by blocking intrinsic apoptosis in lung cancer cells[J].Oncotarget,2014,5(15):6365-6374.
[19]Galluzzi L,BuquéA,Kepp O,et al.Immunogenic cell death in cancer and infectious disease[J].Nat Rev Immunol,2017,17(2):97-111.
[20]van Vloten JP,Workenhe ST,Wootton SK,et al.Critical interactions between immunogenic cancer cell death,oncolytic viruses,and the immune system define the rational design of combination immunotherapies[J].J Immunol,2018,200(2):450-458.
[21]Ye T,Jiang K,Wei L,et al.Oncolytic Newcastle disease virus induces autophagy-dependent immunogenic cell death in lung cancer cells[J].Am J Cancer Res,2018,8(8):1514-1527.
[22]Koks CA,Garg AD,Ehrhardt M,et al.Newcastle disease virotherapy induces long-term survival and tumor-specific immune memory in orthotopic glioma through the induction of immunogenic cell death[J].Int J Cancer,2015,136(5):E313-325.
[23]Zamarin D,Holmgaard RB,Subudhi SK,et al.Localized oncolytic virotherapy overcomes systemic tumor resistance to immune checkpoint blockade immunotherapy[J].Sci Transl Med,2014,6(226):226ra32.
[24]Wei D,Li Q,Wang XL,et al.Oncolytic Newcastle disease virus expressing chimeric antibody enhanced anti-tumor efficacy in orthotopic hepatoma-bearing mice[J].J Exp Clin Cancer Res,2015,34:153.
[25]Bu X,Li M,Zhao Y,et al.Genetically engineered Newcastle disease virus expressing human interferon-λ1 induces apoptosis in gastric adenocarcinoma cells and modulates the Th1/Th2 immune response[J].Oncol Rep,2016,36(3):1393-1402.
[26]Jiang K,Song C,Kong L,et al.Recombinant oncolytic Newcastle disease virus displays antitumor activities in anaplastic thyroid cancer cells[J].BMC Cancer,2018,18(1):746.
[27]Raghunath S,Pudupakam RS,Allen A,et al.Genetically engineered oncolytic Newcastle disease virus mediates cytolysis of prostate cancer stem like cells[J].J Biotechnol,2017,260:91-97.
[28]Farkona S,Diamandis EP,Blasutig IM.Cancer immunotherapy:the beginning of the end of cancer?[J].BMC Med,2016,14:73.
[29]van der Burg SH,Arens R,Ossendorp F,et al.Vaccines for established cancer:Overcoming the challenges posed by immune evasion[J].Nat Rev Cancer,2016,16(4):219-233.
[30]García-Martínez E,Smith M,BuquéA,et al.Trial Watch:Immunostimulation with recombinant cytokines for cancer therapy[J].Oncoimmunology,2018,7(6):e1433982.
[31]Papaioannou NE,Beniata OV,Vitsos P,et al.Harnessing the immune system to improve cancer therapy[J].Ann Transl Med,2016,4(14):261.
[32]Janke M,Peeters B,de Leeuw O,et al.Recombinant Newcastle disease virus(NDV)with inserted gene coding for GM-CSF as a new vector for cancer immunogene therapy[J].Gene Ther,2007,14(23):1639-1649.
[33]Bai F,Niu Z,Tian H,et al.Genetically engineered Newcastle disease virus expressing interleukin 2 is a potential drug candidate for cancer immunotherapy[J].Immunol Lett,2014,159(1/2):36-46.
[34]Ren G,Tian G,Liu Y,et al.Recombinant Newcastle disease virus encoding IL-12 and/or IL-2 as potential candidate for hepatoma carcinoma therapy[J].Technol Cancer Res Treat,2016,15(5):NP83-94.
[35]Wolchok JD,Chiarion-Sileni V,Gonzalez R,et al.Overall survival with combined nivolumab and ipilimumab in advanced melanoma[J].N Engl J Med,2017,377(14):1345-1356.
[36]Zamarin D,Holmgaard RB,Ricca J,et al.Intratumoral modulation of the inducible co-stimulator ICOS by recombinant oncolytic virus promotes systemic anti-tumour immunity[J].Nat Commun,2017,8:14340.
[37]Soussi T,Dehouche K,Beroud C.p53 website and analysis of p53gene mutations in human cancer:Forging a link between epidemiology and carcinogenesis[J].Hum Mutat,2000,15(1):105-113.
[38]Diller L,Kassel J,Nelson CE,et al.p53 functions as a cell cycle control protein in osteosarcomas[J].Mol Cell Biol,1990,10(11):5772-5781.
[39]An Y,Liu T,He J,et al.Recombinant Newcastle disease virus expressing P53 demonstrates promising antitumor efficiency in hepatoma model[J].J Biomed Sci,2016,23(1):55.
[40]Fan X,Lu H,Cui Y,et al.Overexpression of p53 delivered using recombinant NDV induces apoptosis in glioma cells by regulating the apoptotic signaling pathway[J].Exp Ther Med,2018,15(5):4522-4530.
[41]Cuadrado-Castano S,Ayllon J,Mansour M,et al.Enhancement of the proapoptotic properties of newcastle disease virus promotes tumor remission in syngeneic murine cancer models[J].Mol Cancer Ther,2015,14(5):1247-1258.
[42]Wu Y,He J,Geng J,et al.Recombinant Newcastle disease virus expressing human TRAIL as a potential candidate for hepatoma therapy[J].Eur J Pharmacol,2017,802:85-92.